Mar 24, 2025
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY
Mar 19, 2025
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer
Feb 06, 2025
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
Feb 05, 2025
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Dec 02, 2024
First Shipment of Henlius Trastuzumab to U.S.
Nov 08, 2024
Henlius and SVAX Forge Strategic Partnership in the MENAT Market
Sep 21, 2024
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Apr 17, 2024
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity
Mar 21, 2024
Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved
Jan 25, 2024
First International Shipment of HANSIZHUANG
Dec 08, 2020
Henlius Adalimumab Biosimilar Approved by NMPA
Aug 17, 2020
China's First Trastuzumab Biosimilar Approved by NMPA
Jul 29, 2020
Henlius and Accord Healthcare Receive EMA Approval for Zercepac®, trastuzumab biosimilar
Jun 01, 2020
Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)
Apr 23, 2020
Henlius receives EU GMP Certificate for HLX02 (Trastuzumab for Injection)